Literature DB >> 23845795

Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Stephen J Greene1, Mihai Gheorghiade, Muthiah Vaduganathan, Andrew P Ambrosy, Robert J Mentz, Haris Subacius, Aldo P Maggioni, Savina Nodari, Marvin A Konstam, Javed Butler, Gerasimos Filippatos.   

Abstract

AIMS: Haemoconcentration has been studied as a marker of decongestion in patients with hospitalization for heart failure (HHF). We describe the relationship between haemoconcentration, worsening renal function, post-discharge outcomes, and clinical and laboratory markers of congestion in a large multinational cohort of patients with HHF. METHODS AND
RESULTS: In 1684 patients with HHF with ejection fraction (EF) ≤40% assigned to the placebo arm of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial, absolute in-hospital haematocrit change was calculated as the change between baseline and discharge or day 7 (whichever occurred first). Patient characteristics, changes in renal function, and outcomes over a median follow-up of 9.9 months were compared by in-hospital haematocrit change. Overall, 26% of patients had evidence of haemoconcentration (i.e., ≥3% absolute increase in haematocrit). Patients with greater increases in haematocrit tended to have better baseline renal function. Haemoconcentration correlated with greater risk of in-hospital worsening renal function, but renal parameters generally returned to baseline within 4 weeks post-discharge. Patients with haemoconcentration were less likely to have clinical congestion at discharge, and experienced greater in-hospital decreases in body weight and natriuretic peptide levels. After adjustment for baseline clinical risk factors, every 5% increase of in-hospital haematocrit change was associated with a decreased risk of all-cause death [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.70-0.95]. Haematocrit change was also associated with decreased cardiovascular mortality or heart failure (HF) hospitalization at ≤100 days post-randomization (HR 0.73, 95% CI 0.71-0.76).
CONCLUSION: In this large cohort of patients with HHF with reduced EF, haemoconcentration was associated with greater improvements in congestion and decreased mortality and HF re-hospitalization despite an increased risk of in-hospital worsening renal function.

Entities:  

Keywords:  Congestion; Haematocrit; Haemoconcentration; Heart failure; Outcomes; Renal function

Mesh:

Substances:

Year:  2013        PMID: 23845795      PMCID: PMC4199468          DOI: 10.1093/eurjhf/hft110

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  36 in total

1.  Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry.

Authors:  Christopher M O'Connor; Wendy Gattis Stough; Dianne S Gallup; Vic Hasselblad; Mihai Gheorghiade
Journal:  J Card Fail       Date:  2005-04       Impact factor: 5.712

2.  Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

Authors:  Mihai Gheorghiade; Cesare Orlandi; John C Burnett; David Demets; Liliana Grinfeld; Aldo Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Christopher Zimmer; Marvin A Konstam
Journal:  J Card Fail       Date:  2005-05       Impact factor: 5.712

3.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

Authors:  Kirkwood F Adams; Gregg C Fonarow; Charles L Emerman; Thierry H LeJemtel; Maria Rosa Costanzo; William T Abraham; Robert L Berkowitz; Marie Galvao; Darlene P Horton
Journal:  Am Heart J       Date:  2005-02       Impact factor: 4.749

4.  Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure.

Authors:  H M Krumholz; Y T Chen; V Vaccarino; Y Wang; M J Radford; W D Bradford; R I Horwitz
Journal:  Am J Cardiol       Date:  2000-05-01       Impact factor: 2.778

5.  Hemodilution is common in patients with advanced heart failure.

Authors:  Ana-Silvia Androne; Stuart D Katz; Lars Lund; John LaManca; Alhakam Hudaihed; Katarzyna Hryniewicz; Donna M Mancini
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

6.  The prognostic importance of different definitions of worsening renal function in congestive heart failure.

Authors:  Stephen S Gottlieb; William Abraham; Javed Butler; Daniel E Forman; Evan Loh; Barry M Massie; Christopher M O'connor; Michael W Rich; Lynne Warner Stevenson; James Young; Harlan M Krumholz
Journal:  J Card Fail       Date:  2002-06       Impact factor: 5.712

7.  Venous congestion and renal function in heart failure ... it's complicated.

Authors:  Jeffrey M Testani; Kevin Damman
Journal:  Eur J Heart Fail       Date:  2013-04-19       Impact factor: 15.534

8.  Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure.

Authors:  Anju Nohria; Sui W Tsang; James C Fang; Eldrin F Lewis; John A Jarcho; Gilbert H Mudge; Lynne W Stevenson
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

9.  Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study.

Authors:  William M McClellan; W Dana Flanders; Robert D Langston; Claudine Jurkovitz; Rodney Presley
Journal:  J Am Soc Nephrol       Date:  2002-07       Impact factor: 10.121

10.  Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure.

Authors:  Doron Aronson; Murray A Mittleman; Andrew J Burger
Journal:  Am J Med       Date:  2004-04-01       Impact factor: 4.965

View more
  45 in total

Review 1.  The vulnerable phase after hospitalization for heart failure.

Authors:  Stephen J Greene; Gregg C Fonarow; Muthiah Vaduganathan; Sadiya S Khan; Javed Butler; Mihai Gheorghiade
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

2.  A patient with heart failure and worsening kidney function.

Authors:  Mark J Sarnak
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-24       Impact factor: 8.237

Review 3.  Perspective on Clinical Application of Biomarkers in AKI.

Authors:  Chirag R Parikh; Sherry G Mansour
Journal:  J Am Soc Nephrol       Date:  2017-02-20       Impact factor: 10.121

4.  Prognostic value of estimated plasma volume in acute heart failure in three cohort studies.

Authors:  Masatake Kobayashi; Patrick Rossignol; João Pedro Ferreira; Irene Aragão; Yuki Paku; Yoichi Iwasaki; Masataka Watanabe; Marat Fudim; Kevin Duarte; Faiez Zannad; Nicolas Girerd
Journal:  Clin Res Cardiol       Date:  2018-10-19       Impact factor: 5.460

5.  Inhibition of urea transporter ameliorates uremic cardiomyopathy in chronic kidney disease.

Authors:  Akihiro Kuma; Xiaonan H Wang; Janet D Klein; Lin Tan; Nawazish Naqvi; Fitra Rianto; Ying Huang; Manshu Yu; Jeff M Sands
Journal:  FASEB J       Date:  2020-05-04       Impact factor: 5.191

6.  Calculated Estimates of Plasma Volume in Patients With Chronic Heart Failure-Comparison With Measured Volumes.

Authors:  Marat Fudim; Wayne L Miller
Journal:  J Card Fail       Date:  2018-08-08       Impact factor: 5.712

Review 7.  The Basic Metabolic Profile in Heart Failure-Marker and Modifier.

Authors:  Ahmed Elfar; Kamalanathan K Sambandam
Journal:  Curr Heart Fail Rep       Date:  2017-08

8.  Effect on Survival of Concurrent Hemoconcentration and Increase in Creatinine During Treatment of Acute Decompensated Heart Failure.

Authors:  Matthew Griffin; Veena S Rao; James Fleming; Parinita Raghavendra; Jeffrey Turner; Devin Mahoney; Nicholas Wettersten; Alan Maisel; Juan B Ivey-Miranda; Lesley Inker; Wai Hong Wilson Tang; Francis Perry Wilson; Jeffrey M Testani
Journal:  Am J Cardiol       Date:  2019-09-06       Impact factor: 2.778

Review 9.  Improving Postdischarge Outcomes in Acute Heart Failure.

Authors:  Ovidiu Chioncel; Sean P Collins; Andrew P Ambrosy; Peter S Pang; Elena-Laura Antohi; Vlad Anton Iliescu; Aldo P Maggioni; Javed Butler; Alexandre Mebazaa
Journal:  Am J Ther       Date:  2018 Jul/Aug       Impact factor: 2.688

10.  Optimal Endpoints of Acute Heart Failure Therapy.

Authors:  Jessica H Huston; Robinson Ferre; Peter S Pang; Ovidiu Chioncel; Javed Butler; Sean Collins
Journal:  Am J Ther       Date:  2018 Jul/Aug       Impact factor: 2.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.